Just like TNBC, the purpose of AR in the management of estrogen receptor-optimistic (ER+) breast cancer is a region of active investigate. AR is expressed in as many as 90% of ER+ tumors and preclinical facts suggests that AR expression is linked to resistance to both tamoxifen and aromatase inhibit